Table 4.
Outcome | Study | No. of patients (O/N) | MD (95 % CI) | P for MD | I2 | P for heterogeneity |
---|---|---|---|---|---|---|
EQ-5D at 12 mo | Olerud et al. (2011a, b) | 53/52 | 0.08 (−0.01, 0.17) | 0.10 | 0 % | 0.83 |
EQ-5D at 24 mo | Olerud et al. (2011a, b) | 51/51 | 0.15 (0.05, 0.24) | 0.004 | 0 % | 0.65 |
15D at 12 mo | Fjalestad et al. (2012) | 23/25 | 0.02 (−0.03, 0.07) | 0.44 | NA | NA |
15D at 24 mo | Fjalestad et al. (2012) | 23/25 | 0.02 (−0.78, 0.83) | 0.95 | NA | NA |